Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

By B. Keymeulen, E. Vandemeulebroucke, A. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon and 15 more. New England Journal of Medicine, 2005

1,080 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/d647782756375a73aa4a97b2b24411a2fd88863c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. A. Michels
2. Mark Atkinson
3. G. Eisenbarth

In Genetics

1. A. Michels
2. Mark Atkinson
3. G. Eisenbarth

In Immunology

1. A. Tedgui
2. Z. Mallat
3. R. Medzhitov

Citations in the corpus

• Cytokines in atherosclerosis: pathogenic and regulatory pathways. (2006, background): “Interestingly, use of a humanized antiCD3 antibody in patients with recent-onset type 1 diabetes shows that short-term treatment preserves residual -cell function for at least 18 mo (333).”
• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes (2019, neutral): “Pulmonary or upper respiratory 6 4 (9) 0 0”
• Type 1 diabetes (2013, background): “These results include an intervention with the anti-CD3 monoclonal antibodies teplizumab ( A ) [ 21 ] and otelixizumab ( B ) [ 22 ] , the anti-CD20 monoclonal antibody rituximab ( C ) [ 23 ] , and a GAD vaccine ( D ) [ 24 ] .”